LAB INTERNATIONAL COMPLETES PATIENT ENROLLMENT IN FENTANYL TAIFUN TRIAL

LAB International has completed patient enrollment for the pivotal Phase IIa trial of its lead product, Fentanyl Taifun.

The multicenter, randomized, double blind, placebo-controlled Phase II trial is investigating the efficacy and safety of Fentanyl Taifun for the treatment of breakthrough cancer pain, monitoring response at different Fentanyl doses. The trial enrolled a total of 122 cancer patients on maintenance opioid therapy for persistent pain.